Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-19
2011-07-19
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07981868
ABSTRACT:
Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.
REFERENCES:
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5856462 (1999-01-01), Agrawal
patent: 5872242 (1999-02-01), Monia et al.
patent: 5877309 (1999-03-01), Dean et al.
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 6140124 (2000-10-01), Monia et al.
patent: 6448079 (2002-09-01), Monia et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6906186 (2005-06-01), Wyatt et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0176383 (2003-09-01), Monia et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0171566 (2004-09-01), Monia et al.
patent: WO 91/14002 (1991-09-01), None
patent: WO 97/04104 (1997-02-01), None
patent: 9835978 (1998-08-01), None
patent: 9960166 (1999-11-01), None
patent: WO 00/59919 (2000-10-01), None
Skerra, A. (Nucleic Acids Research, 1992 vol. 20:3551-3554).
Branch, AD. A good antisense molecule is hard to find. TIBS, 1998 vol. 23:45-50.
Escott, K.G., etal., “Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat,” British Journal of Pharmacology (2000) 131:173-176.
Taube, et al., Inhibition of Early Airway Neutrophilia Does Not Affect Development of Airway Hyperresponsiveness, 2004, American Journal of Respiratory Cell and Molecular Biology, vol. 30 pp. 837-843.
Underwood, et al., SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistance, 2000, The Journal of Pharmacology and Experimental Therapeutics, vol. 293, No. 1, pp. 281-288.
Agrawal, S. et al., “Antisense therapeutics: is it as simple as complementary base recognition?” Molecular Medicine Today (2000) 6:72-81.
Aoshiba, K. et al., “Role of p38-Mitogen-Activated Protein Kinase in Spontaneous Apoptosis of Human Neutrophils,” J. Immunol. (1999) 162:1692-1700.
Arima, H. et al., “Specific Inhibition of Nitric Oxide Production in Macrophages by Phosphorothioate Antisense Oligonucleotides,” J. Pharm. Sci. (1997) 86(10):1079-1084.
Branch, A. D., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chialda, L. et al., “Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia,” Respiratory Research (2005) 6:36.
Cohen, P. S. et al., “The Critical Role of p38 MAP Kinase in T Cell HIV-1 Replication,” Molecular Medicine (1997) 3(5):339-346.
Crooke, S. T., “Basic Principles of Antisense Therapeutics,” Antisense Research and Application (1998) Springer-Verlag, New York, pp. 1-50.
Database EMBL:HS1206359 “zv26e08.s1 Soares—NhHMPu—S1Homo sapienscDNA clone IMAG:754790 3′ similar to TR:G1304132 G1304132 TPRD.;, mRNA sequence,” May 4, 1997 XP002302626 retrieved from EBI accession No. EM—EST:1206359 Database accession No. HS1206359.
Duan, W. et al., “Inhaled p38 Mitogen-Activated Protein Kinase Antisense Oligonucleotides Attenuates Asthma in Mice,” Am. J. Respir. Crit. Care Med. (2005) 171:571-578.
Green, D. W. et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,” J. Am. Coll. Surg. (2000) 191:93-105.
Han, J. et al., “A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells,” Science (1994) 265:808-811.
Jen, K.-Y. et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” Stem Cells (2000) 18:307-319.
Kumar, R. K. et al., “Murine Model of Chronic Human Asthma,” Immunology and Cell Biology (2001) 79:141-144.
Nagata, Y. et al., “Activation of p38 MAP Kinase and JNK But Not ERK Is Required for Erythropoietin-Induced Erythroid Differentiation,” Blood (1998) 92(6):1859-1869.
Nick, J. A. et al., “Role of p38 Mitogen-Activated Protein Kinase in a Murine Model of Pulmonary Inflammation,” J. Immunol. (2000) 164:2151-2159.
Nyce, J. W., “Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases,” Expert. Opin. Investig. Drugs (1997) 6(9):1149-1156.
Nyce, J. W. et al., “DNA antisense therapy for asthma in an animal model,” Nature (1997) 385(6618):721-725.
Richards, I. M., “Mouse models of allergic disease; how do they relate to asthma in man?” Clinical and Experimental Allergy (1996) 26:618-620.
Sale, E. M. et al., “Use of an antisense strategy to dissect the role of MAP kinases in cellular signaling,” Biochemical Society Transactions (1998) 26(3):S254.
Temelkovski, J. et al., “An improved murine model of asthma selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen,” Thorax (1998) 53:849-856.
Wong, W. S. F., “Inhibitors of the tyrosine kinase signaling cascade for asthma,” Current Opinion in Pharmacology (2005) 5:264-271.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Gura, Trisha. Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
New England BioLabs, Inc. Catalogue (1998): 121, 284.
Reynolds et al., Rational siRNA design for RNA interference, Mar. 2004, Nature Biotechnology, vol. 22, pp. 326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
GenBank Accession No. L35253.
International Search Report from PCT/US2004/026344, dated Nov. 21, 2005.
Supplementary European Search Report from EP 04 78 1089, dated Jan. 9, 2007.
Supplementary European Search Report from EP 04 78 1089, dated Oct. 20, 2006.
Han et al., “Molecular cloning of human p38 MAP kinase” Biochimica et Biophysica Acta (1995) 1265:224-227.
Supplementary Partial European Search Report for Application No. EP 00920053.6 dated Aug. 30, 2004.
Supplementary Partial European Search Report for Application No. EP 00920053.6 dated Nov. 23, 2004.
International Search Report for Application No. PCT/US00/08794 dated Aug. 7, 2000.
Dobie Kenneth W.
Freier Susan M.
Karras James G.
Monia Brett P.
Popoff Ian
Gibbs Terra Cotta
ISIS Pharmaceuticals Inc.
Knobbe Martens Olson & Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of p38 mitogen activated protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of p38 mitogen activated protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of p38 mitogen activated protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645658